Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Xencor Inc | XNCR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
19.02 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 16.49 - 28.96 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 19.02 | USD |
Xencor Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.16B | 61.12M | - | 168.34M | -126.09M | -2.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Xencor News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XNCR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 19.08 | 19.18 | 17.945 | 18.60 | 611,151 | -0.06 | -0.31% |
1 Month | 22.49 | 22.70 | 17.945 | 20.17 | 549,156 | -3.47 | -15.43% |
3 Months | 18.77 | 26.84 | 17.945 | 22.01 | 705,547 | 0.25 | 1.33% |
6 Months | 17.96 | 26.84 | 16.49 | 20.96 | 626,919 | 1.06 | 5.90% |
1 Year | 28.18 | 28.96 | 16.49 | 21.84 | 472,528 | -9.16 | -32.51% |
3 Years | 44.11 | 44.80 | 16.49 | 26.86 | 362,641 | -25.09 | -56.88% |
5 Years | 31.82 | 58.345 | 16.49 | 30.88 | 360,222 | -12.80 | -40.23% |
Xencor Description
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates. |